Zura Bio Limited: shareholders and insiders

ZURANASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$0.93

November 20, 2026Market cap $119M

What Ploutos Investor adds for Zura Bio

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 4 fiscal years, from 2022
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 78% since Oct 27, 2026, when the 10-Q these figures come from was filed ($4.27 then, $0.93 on Nov 20, 2026). The figures date from before that move.10-Q

Insiders and their shares

Purchases and sales by officers and directors from Nov 22, 2025 to Jun 22, 2026, from their own Form 4 filings.

7 Form 4s

Bought on the market

$13M

1 person

Sold on the market

–

nobody

From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

No sales in the period.

  • Feb 26, 2026Access Industries Holdings LLC
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 22, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by ZURA's officers and directors from 2023 up to November 21, 2025, 3 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

4 Holders over 5%2 On a 13DMay 15, 2026 Latest filing
  • AI Biotechnology LLCwith 3 more personsClass A Ordinary Shares, par value $0.0001 per share
    Share of class18.2%
  • Athanor Capitalwith 1 more personClass A Ordinary Shares, par value $0.0001 per share
    Share of class15.7%
  • Suvretta Capital Management, LLCwith 2 more personsClass A Ordinary Shares, par value $0.0001 per share
    Share of class9.90%
  • Venrock Healthcare Capital Partners III, L.P.with 6 more personsClass A Ordinary Shares, par value $0.0001 per share
    Share of class9.90%

What the holders on a 13D state as their purpose

From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.

  • AI Biotechnology LLC18.2%From the filing of May 28, 2025

    The information set forth in Item 6 hereof is hereby incorporated herein by reference. The Reporting Persons who hold securities of the Issuer directly acquired those securities as an investment in the regular course of their businesses. The Reporting Persons may engage in discussions with management, the Issuer's board of directors, other stockholders of the Issuer and other relevant parties concerning the business, operations, board composition, management, strategy and future plans of the Issuer. Dan Becker, Managing Director at Access Biotechnology, the biopharmaceutical investing arm of Access Industries, currently serves on the board of directors of the Issuer. The Reporting Persons…

    From the filing of May 28, 2025
  • Athanor Capital15.7%From the filing of Jan 27, 2026

    The securities reported herein were acquired by the Reporting Persons for investment purposes in the ordinary course of business. The Reporting Persons acquired the securities without the purpose or effect of changing or influencing the control of the Issuer and do not have any present plans or proposals that relate to or would result in any of the actions described in Items 4(a) through 4(j) of Schedule 13D. The Reporting Persons may, from time to time, review their investment in the Issuer and may engage in discussions with management or the board of directors of the Issuer regarding the Issuer's business, operations and prospects, subject to applicable law. The Reporting Persons reserve…

    From the filing of Jan 27, 2026
Fell to 5% or less (6)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • Great Point Partners, LLC4.44%May 15, 202613G/A
  • JPMorgan Chase4.70%May 6, 202613G/A
  • Deep Track Capital, LP0.40%Nov 14, 202513G/A
  • ADAR1 Capital Management, LLC3.18%Feb 14, 202513G/A
  • RA Capital Management, L.P.4.90%Feb 14, 202513G/A
  • Pfizer Inc. 13-53151704.60%Feb 12, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Citadel Advisors (Griffin)
    In the quarter+213%
  • Millennium Mgmt (Englander)
    In the quarter+442%
  • D.E. Shaw
    In the quarter
  • Renaissance Technologies
    In the quarter-84%
  • AQR Capital
    In the quarter

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 5.50% of its shares outstanding were held short, -25.1% since the report before.

Shares held short
7.02M
5.50%
Since the report before9.37M on Sep 30, 2026
-25.1%
1.5
4.78M
More days to cover thanof 4,578 US-listed companies with enough volume
20%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 461.9K
  • Nov 15, 2023: Shares held short 171.2K
  • Nov 30, 2023: Shares held short 173.0K
  • Dec 15, 2023: Shares held short 215.9K
  • Dec 29, 2023: Shares held short 436.9K
  • Jan 12, 2024: Shares held short 352.9K
  • Jan 31, 2024: Shares held short 328.5K
  • Feb 15, 2024: Shares held short 383.1K
  • Feb 29, 2024: Shares held short 358.2K
  • Mar 15, 2024: Shares held short 330.0K
  • Mar 28, 2024: Shares held short 628.3K
  • Apr 15, 2024: Shares held short 428.4K
  • Apr 30, 2024: Shares held short 400.5K
  • May 15, 2024: Shares held short 721.4K
  • May 31, 2024: Shares held short 569.7K
  • Jun 14, 2024: Shares held short 643.4K
  • Jun 28, 2024: Shares held short 710.1K
  • Jul 15, 2024: Shares held short 1.79M
  • Jul 31, 2024: Shares held short 3.44M
  • Aug 15, 2024: Shares held short 4.02M
  • Aug 30, 2024: Shares held short 663.3K
  • Sep 13, 2024: Shares held short 849.7K
  • Sep 30, 2024: Shares held short 1.86M
  • Oct 15, 2024: Shares held short 1.88M
  • Oct 31, 2024: Shares held short 1.75M
  • Nov 15, 2024: Shares held short 4.96M
  • Nov 29, 2024: Shares held short 5.16M
  • Dec 13, 2024: Shares held short 5.01M
  • Dec 31, 2024: Shares held short 4.95M
  • Jan 15, 2025: Shares held short 4.99M
  • Jan 31, 2025: Shares held short 4.88M
  • Feb 14, 2025: Shares held short 5.13M
  • Feb 28, 2025: Shares held short 5.23M
  • Mar 14, 2025: Shares held short 5.31M
  • Mar 31, 2025: Shares held short 5.37M
  • Apr 15, 2025: Shares held short 2.59M
  • Apr 30, 2025: Shares held short 2.49M
  • May 15, 2025: Shares held short 2.51M
  • May 30, 2025: Shares held short 3.08M
  • Jun 13, 2025: Shares held short 2.67M
  • Jun 30, 2025: Shares held short 1.16M
  • Jul 15, 2025: Shares held short 585.9K
  • Jul 31, 2025: Shares held short 534.4K
  • Aug 15, 2025: Shares held short 544.6K
  • Aug 29, 2025: Shares held short 425.3K
  • Sep 15, 2025: Shares held short 458.1K
  • Sep 30, 2025: Shares held short 2.05M
  • Oct 15, 2025: Shares held short 2.62M
  • Oct 31, 2025: Shares held short 2.72M
  • Nov 14, 2025: Shares held short 2.57M
  • Nov 28, 2025: Shares held short 2.54M
  • Dec 15, 2025: Shares held short 2.60M
  • Dec 31, 2025: Shares held short 2.85M
  • Jan 15, 2026: Shares held short 3.01M
  • Jan 30, 2026: Shares held short 3.85M
  • Feb 13, 2026: Shares held short 4.08M
  • Feb 27, 2026: Shares held short 4.74M
  • Mar 13, 2026: Shares held short 5.11M
  • Mar 31, 2026: Shares held short 5.75M
  • Apr 15, 2026: Shares held short 6.15M
  • Apr 30, 2026: Shares held short 6.97M
  • May 15, 2026: Shares held short 6.24M
  • May 29, 2026: Shares held short 6.22M
  • Jun 15, 2026: Shares held short 5.87M
  • Jun 30, 2026: Shares held short 9.24M
  • Jul 15, 2026: Shares held short 10.25M
  • Jul 31, 2026: Shares held short 10.51M
  • Aug 14, 2026: Shares held short 11.44M
  • Aug 31, 2026: Shares held short 11.10M
  • Sep 15, 2026: Shares held short 9.34M
  • Sep 30, 2026: Shares held short 9.37M
  • Oct 15, 2026: Shares held short 7.02M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading43.3% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 43.3% of the shares in the reported trades were short sales, against 48.4% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
43.3%
The 14 beforeOct 14, 2026 – Nov 2, 2026
48.4%
Change
-5.1 pts
Short sales a dayon average, of 4.83M shares
2.09M
More than atof 3,666 US-listed companies, same days
28%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 52.9%
  • Oct 15, 2026: Short sales 54.5%
  • Oct 16, 2026: Short sales 64.5%
  • Oct 19, 2026: Short sales 39.2%
  • Oct 20, 2026: Short sales 29.2%
  • Oct 21, 2026: Short sales 21.2%
  • Oct 22, 2026: Short sales 49.9%
  • Oct 23, 2026: Short sales 52.8%
  • Oct 26, 2026: Short sales 59.5%
  • Oct 27, 2026: Short sales 34.6%
  • Oct 28, 2026: Short sales 39.4%
  • Oct 29, 2026: Short sales 61.8%
  • Oct 30, 2026: Short sales 67.9%
  • Nov 2, 2026: Short sales 45%
  • Nov 3, 2026: Short sales 43%
  • Nov 4, 2026: Short sales 56.8%
  • Nov 5, 2026: Short sales 57%
  • Nov 6, 2026: Short sales 57.2%
  • Nov 9, 2026: Short sales 56.1%
  • Nov 10, 2026: Short sales 17.2%
  • Nov 11, 2026: Short sales 23.5%
  • Nov 12, 2026: Short sales 18.3%
  • Nov 13, 2026: Short sales 8.4%
  • Nov 16, 2026: Short sales 24.9%
  • Nov 17, 2026: Short sales 47.7%
  • Nov 18, 2026: Short sales 50.7%
  • Nov 19, 2026: Short sales 40.6%
  • Nov 20, 2026: Short sales 31.5%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

5 ETFs holding it0.08% The largest weight (IWC)
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.08%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.02%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.01%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.01%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.00%

5 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

95 Managers, Q2 2026$429M Value of their positions
  • Q3 2025: Managers 66
  • Q4 2025: Managers 74
  • Q1 2026: Managers 95
  • Q2 2026: Managers 95

Institutional investors by quarter

The fund managers holding ZURA, quarter by quarter, from Q1 2023 to Q2 2025, 10 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 95 managers held 72.94M shares, worth $429M. During the quarter 25 opened a position, 26 closed one, 31 added and 19 trimmed.

The largest holders, Q2 2026

  • Montanova Capital
    In the quarter+4.1%
  • Venrock Adviser
    In the quarter
  • Mpm Bioimpact
    In the quarter
  • JPMorgan Chase
    In the quarter-2.3%
  • Great Point Partners
    In the quarter
  • Braidwell
    In the quarter-0.2%
  • Siren
    In the quarter
  • BlackRock
    In the quarter+690%
  • Commodore Capital
    In the quarter
  • Adage Capital Partners Gp
    In the quarter

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Zura Bio's filings show?

Who buys and sells is one part of Zura Bio's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ZURA's shareholders

Didn't find what you were looking for?

Ask us
Have ZURA's insiders bought or sold?

From Jun 22, 2026 to Jun 22, 2026 Zura Bio's insiders reported no purchase or sale of shares on the market.

Which well-known managers hold ZURA?

5 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $3.9M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.